HIV Treatment Bulletin - Vol. 7, No. 6, June 2006

The Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents was revised in May 2006.

Changes to these guidelines include new recommendations for resistance testing, treatment interruption, and HBV/HIV co-infection. Tables have been revised to include up-to-date information about drug interactions and about the lopinavir/ritonavir 200/50 mg tablet formulation (Meltrex).

AIDSinfo - HIV / Medical Practice Guidelines

Comment

The recommendation for genotypic resistance testing cover newly diagnosed individuals (whether or not they are considering ARV treatment) and all treatment naïve patients before starting treatment. This was first included in BHIVA guideline in 2003.

The recommendation for starting treatment remains ‘ when CD4 count is 200-350 cells/mm³, and first-line therapy remains: efavirenz plus 3TC/FTC plus AZT/tenofovir; or lopinavir/r plus 3TC/FTC plus AZT.

One of the key differences between UK guidelines is the continued use of AZT as a preferred first-line choice of nucleoside, without any reference to recent research showing that AZT causes lipoatrophy. AZT remains unlisted as a cause of lipoatrophy in both the text and in the tables summarising side effects. Evidence supporting this risk was considered sufficiently strong for this caution to be introduced in the UK guidelines in July 2005.

Recommendations for management of patients coinfected with hepatitis B, includes not using 3TC, FTC or tenofovir as the only HBV-active treatment in HAART regimens, due to the risk of HBV resistance to these agents.

While BHIVA guidelines only recommend use of boosted-PI regimens, the US guidelines only recommend boosting atazanavir when used with tenofovir or efavirenz, and include un-boosted fosamprenavir as an alternative option.

The US guidelines also include several references to drugs that are now discontinued, including saquinavir sgc (Fortovase), ddC (zalcitabine) and amprenavir (Agenerase), though these may have been retained for historical reasons.

2006-06-10
IB060706-23

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.